Research output per year
Research output per year
Personal profile
Research interests
My area of research is in genomics, immunotherapy and clinical trials for patients with thoracic malignancies.
Clinical interests
Medical oncology, lung cancer
Fingerprint
Dive into the research topics where Daniel Morgensztern is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
Camidge, D. R., Barlesi, F., Goldman, J. W., Morgensztern, D., Heist, R., Vokes, E., Spira, A., Angevin, E., Su, W. C., Hong, D. S., Strickler, J. H., Motwani, M., Dunbar, M., Parikh, A., Noon, E., Blot, V., Wu, J. & Kelly, K., Feb 10 2023, In: Journal of Clinical Oncology. 41, 5, p. 1105-1115 11 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Trends in Stage I Lung Cancer
Singareddy, A., Flanagan, M. E., Samson, P. P., Waqar, S. N., Devarakonda, S., Ward, J., Herzog, B. H., Rohatgi, A., Robinson, C., Gao, F., Govindan, R., Puri, V. & Morgensztern, D., Mar 2023, In: Clinical Lung Cancer. 24, 2, p. 114-119 6 p.Research output: Contribution to journal › Article › peer-review
-
A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC
Camidge, D. R., Barlesi, F., Goldman, J. W., Morgensztern, D., Heist, R., Vokes, E., Angevin, E., Hong, D. S., Rybkin, I. I., Barve, M., Bauer, T. M., Delmonte, A., Dunbar, M., Motwani, M., Parikh, A., Noon, E., Wu, J., Blot, V. & Kelly, K., Jan 2022, In: JTO Clinical and Research Reports. 3, 1, 100262.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer
Knapp, B., Mezquita, L., Devarakonda, S., Aldea, M., Waqar, S. N., Pepin, K., Ward, J. P., Botticella, A., Howarth, K., Knape, C., Morris, C., Govindan, R., Besse, B. & Morgensztern, D., Mar 28 2022, In: Frontiers in Oncology. 12, 856132.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers
Felip, E., Moreno, V., Morgensztern, D., Curigliano, G., Rutkowski, P., Trigo, J. M., Calvo, A., Kowalski, D., Cortinovis, D., Plummer, R., Maio, M., Ascierto, P. A., Vladimirov, V. I., Cervantes, A., Zudaire, E., Hazra, A., T’jollyn, H., Bandyopadhyay, N., Greger, J. G., Attiyeh, E., & 2 others, Apr 2022, In: Cancer Chemotherapy and Pharmacology. 89, 4, p. 499-514 16 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations